Veracyte
VCYT | NASDAQ
$24.01
-$0.32 (-1.32%)
At close: Nov 16, 2026, 4:00 PM ET
$23.50
-$0.51 (-2.12%)
After-hours:
Nov 16, 2026, 7:46 PM ET
Veracyte Company Profile
Company profile explainedCompany Profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| Marc A. Stapley | Chief Executive Officer & Director |
| Rebecca Chambers | Executive Vice President & Chief Financial Officer |
| Steven French | Senior Vice President & Chief Information Officer |
| Annie McGuire | Executive VP, General Counsel & Head of Market Access |
| John Leite | Global Chief Commercial Officer |
| Jonathan Wygant | Vice President & Chief Accounting Officer |
| Karen Possemato | Senior Vice President of Corporate Marketing, Communications & Commercial Operations |
| Keith Gligorich | Senior Vice President of Global Operations |
| Kelly Gura | Director of Investor Relations |
| Kevin Richard Haas | Chief Development and Technology Officer |
| Phillip G. Febbo | Chief Scientific & Medical Officer |
| Tracy Ward | Chief Human Resources Officer |
Veracyte
| Country | United States |
| IPO Date | Oct 29, 2013 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 755 |
| CEO | Marc Stapley |
Contact Details
6000 Shoreline Court South San Francisco,
California 94080 United States
Stock Details
| Ticker Symbol | VCYT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001384101 |
| CUSIP Number | 92337F107 |
| ISIN Number | US92337F1075 |
| SIC Code | 8071 |
Recent News
- 4 days ago / seekingalpha.comVeracyte: Solid Profits, Slowing Tests, And A Stock In Limbo
- 6 days ago / seekingalpha.comVeracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript
- 11 days ago / zacks.comVeracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
- 11 days ago / prnewswire.comVCYT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Veracyte
- 11 days ago / seekingalpha.comVeracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript
- 12 days ago / marketbeat.comWhat Veracyte (VCYT) Said on Its Q3 Earnings Call
- 12 days ago / zacks.comVeracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
- 18 days ago / globenewswire.comVeracyte to Participate in Upcoming Investor Conferences
- 20 days ago / zacks.comVeracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- 25 days ago / globenewswire.comPhase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
Add to Watchlist
Select watchlists to add or remove VCYT